Allergy clinical trials

Explore recruiting allergy clinical trials.

Recruiting allergy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Allergy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects with Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis with or without Asthma Induced by House Dust Mite (HDM) Allergy

Lithuania, Germany, Latvia, Bulgaria, Poland, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

EPITOPE Open-label Extension Study to Evaluate the Long-term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children (EPOPEX)

Germany, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

PROlonged versus Single dose in PEnicillin oral Challenge Testing double-blind parallel randomized placebo cOntrolled tRial – PROSPECTOR-2 Study

Belgium, Denmark

Therapeutic use (Phase IV) EU CTIS Study details

A three-year, multi-center, double-blind, extension study to evaluate the long-term safety and efficacy of ligelizumab in patients who completed ligelizumab’s Phase III studies in food allergy

Netherlands, France, Spain, Italy, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Lepidoglyphus destructor extract. Determination of in vivo allergenic potency in histamine equivalent prick testing units (HEP).

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Sublingual Birch Immunotherapy for Pollen-associated Food Allergy

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Allergy trials by city

Allergy in Toronto Allergy in Vancouver Allergy in Montreal Allergy in Calgary Allergy in Edmonton Allergy in Ottawa Allergy in Winnipeg Allergy in Quebec City Allergy in Hamilton Allergy in Kitchener Allergy in London Allergy in Halifax Allergy in New York Allergy in Los Angeles Allergy in Chicago Allergy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease